新規アデニン化合物

Novel adenine compound

Nouveau composé adénine

Abstract

La présente invention concerne un nouveau composé adénine représenté par la formule (1) : (1) [dans laquelle Z représente un groupe alkylène substitué ou non substitué, une liaison simple, etc. ; R1 représente un groupe alkyle, alcényle, alcynyle, cycloalkyle, aryle ou hétéroaryle substitué ou non substitué ; R2 représente un atome d’hydrogène ou un groupe alkyle substitué ou non substitué ; R3, R4 et R5 représentent chacun indépendamment un groupe alkyle, alcényle, alcynyle, aryle ou hétéroaryle substitué ou non substitué, à condition que R3 et R5 puissent être liés ensembles pour former un carbocycle ou un hétérocycle saturé de 3 à 7 chaînons en conjonction avec l'atome de carbone adjacent ; et X représente un atome d’oxygène, de soufre, SO2, NR6 (R6 représente un atome d’hydrogène ou un groupe alkyle) ou une liaison simple] ou un sel du composé pharmaceutiquement acceptable. Le composé et le sel sont utiles comme médicament.
A novel adenine compound represented by the formula (1): (1) [wherein Z represents (un)substituted alkylene, a single bond, etc.; R1 represents an (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl group; R2 represents hydrogen or (un)substituted alkyl; R3, R4, and R5 each independently represents an (un)substituted alkyl, alkenyl, alkynyl, aryl, or heteroaryl group, provided that R3 and R5 may be bonded to each other to form a 3- to 7-membered, saturated carbocycle or heterocycle in cooperation with the adjacent carbon atom; and X represents oxygen, sulfur, SO2, NR6 (R6 represents hydrogen or alkyl), or a single bond] or a pharmaceutically acceptable salt of the compound. The compound and salt are useful as a medicine.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (15)

    Publication numberPublication dateAssigneeTitle
    JP-H10501533-AFebruary 10, 1998バイオケム・ファーマ・インコーポレーテッド免疫調節活性を有する新規な置換プリニル誘導体
    US-4689338-AAugust 25, 1987Riker Laboratories, Inc.1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
    WO-0040529-A1July 13, 2000Angiogene Pharmaceuticals Ltd.Derives de colchinol utilises comme agents de degradation vasculaire
    WO-0041669-A2July 20, 2000Angiogene Pharmaceuticals Ltd.Benzimidazole vascular damaging agents
    WO-0192224-A1December 06, 2001Astrazeneca Ab, Astrazeneca Uk LimitedDerives d'indole possedant une activite endommageant les vaisseaux sanguins
    WO-0204434-A1January 17, 2002Angiogene Pharmaceuticals LimitedDerives de colchinol utilises comme agents de degradation vasculaire
    WO-0208213-A1January 31, 2002Angiogene Pharmaceuticals LimitedDerives de colchinol utiles comme inhibiteurs de l'angiogenese
    WO-2004029054-A1April 08, 2004Sumitomo Pharmaceuticals Company, LimitedNovel adenine compound and use thereof
    WO-9722596-A1June 26, 1997Zeneca Limited, Zeneca-Pharma S.A.Quinazoline derivatives
    WO-9730035-A1August 21, 1997Zeneca Limited, Zeneca Pharma S.A.Derives de la quinazoline utilises comme inhibiteurs du vegf
    WO-9732856-A1September 12, 1997Zeneca Limited, Zeneca Pharma S.A.Derives de 4-anilinoquinazoline
    WO-9801448-A1January 15, 1998Japan Energy CorporationNouveaux derives de purine
    WO-9813354-A1April 02, 1998Zeneca Limited, Zeneca Pharma S.A.Derives quinazolines et compositions pharmaceutiques les contenant
    WO-9902166-A1January 21, 1999Angiogene Pharmaceuticals Ltd.Utilisation de derives de colchinol comme agents de degradation vasculaire
    WO-9928321-A1June 10, 1999Sumitomo Pharmaceuticals Company, Limited, Japan Energy CorporationNouveaux composes heterocycliques

NO-Patent Citations (6)

    Title
    "Jikken-Kagaku-Koza"
    "Jikken-Kagaku-Koza", vol. 1
    "Protective Groups in Organic Synthesis", 1990, JOHN WILEY & SONS
    LEE J. ET AL.: "Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7", PROC. NATL. ACAD. SCI. USA, vol. 100, no. 11, 2003, pages 6646 - 6651, XP002307483
    R. C. LAROCK: "Comprehensive Organic Transformation", 1989, VCH PUBLISHERS, INC
    See also references of EP 1939200A4

Cited By (22)

    Publication numberPublication dateAssigneeTitle
    JP-2010513257-AApril 30, 2010アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag, 大日本住友製薬株式会社免疫調節剤としての8−オキソアデニン誘導体
    JP-2010522150-AJuly 01, 2010アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag, 大日本住友製薬株式会社Toll様受容体(tlr7)モジュレーターとしての9−置換−8−オキソ−アデニン化合物
    US-8012964-B2September 06, 2011Dainippon Sumitomo Pharma Co., Ltd., Astrazeneca Aktiebolag9-substituted 8-oxoadenine compound
    US-8044056-B2October 25, 2011Dainippon Sumitomo Pharma Co., Ltd., Astrazeneca AktiebolagAdenine compound
    US-8063051-B2November 22, 2011Astrazeneca Ab, Dainippon Sumitomo Pharma Co., Ltd.9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators
    US-8067411-B2November 29, 2011Astrazeneca Ab, Dainippon Sumitomo Pharma Co., Ltd.Compounds
    US-8067413-B2November 29, 2011Astrazeneca Ab, Dainippon Sumitomo Pharma Co., Ltd.9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators
    US-8138172-B2March 20, 2012Astrazeneca Ab, Dainippon Sumitomo Pharma Co Ltd.8-oxoadenine derivatives acting as modulators of TLR7
    US-8268990-B2September 18, 2012Astrazeneca Ab, Dainippon Sumitomo Pharma Co., Ltd.Compounds
    US-8476288-B2July 02, 2013Astrazeneca Ab, Dainippon Sumitomo Pharma Co., Ltd.Salts 756
    US-8507507-B2August 13, 2013Gilead Sciences, Inc.Modulators of toll-like receptors
    US-8575180-B2November 05, 2013Astrazeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.9-substituted 8-oxoadenine compound
    US-8765939-B2July 01, 2014Astrazeneca Ab, Dainippon Sumitomo Pharma Co., Ltd.Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers
    US-8865896-B2October 21, 2014Astrazeneca Aktiebolag, Dainippon Sumitomo Pharma Co., Ltd.Method for preparing adenine compound
    US-8895570-B2November 25, 2014Astrazeneca AbPurine derivatives
    US-8962652-B2February 24, 2015Gilead Sciences, Inc.Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
    US-8969362-B2March 03, 2015Astrazeneca Aktiebolag, Sumitomo Dainippon Pharma Co., Ltd.9-substituted 8-oxoadenine compound
    US-9045472-B2June 02, 2015Astrazeneca Ab, Sumitomo Dainippon Pharma Co., Ltd.Imidazoquinoline compounds
    US-9161934-B2October 20, 2015Gilead Sciences, Inc.Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
    US-9376398-B2June 28, 2016Sumitomo Dainippon Pharma Co., Ltd, Astrazeneca AktiebolagCarboxylic acid compounds
    WO-2008114006-A1September 25, 2008Astrazeneca Ab, Dainippon Sumitomo Pharma Co., Ltd., Astrazeneca Uk LimitedComposés de 8 oxo-adenine 9 substitué comme modulateurs du récepteur de type toll (tlr7)
    WO-2008114008-A1September 25, 2008Astrazeneca Ab, Dainippon Sumitomo Pharma Co., Ltd., Astrazeneca Uk Limited9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators